Washington Research Foundation (WRF) has awarded a $250,000 phase 2 technology commercialization grant to Anindya…
kchenJuly 12, 2021
Three mutations in the Epsilon coronavirus spike protein dampen the neutralizing potency of antibodies induced…
kchenJuly 9, 2021
Seattle-based Icosavax has filed to go public via an IPO, just four years after it launched out…
kchenJuly 8, 2021
An experimental COVID-19 vaccine in development by Seattle-based HDT Bio will enter early-stage clinical trials in the…
kchenJuly 8, 2021
One key focus within our lab is to better understand signaling events that alter lymphocyte…
kchenJuly 7, 2021
The response of patients with recurrent glioblastoma multiforme to neoadjuvant immune checkpoint blockade has been…
kchenJuly 6, 2021
HDT Bio Corp., a developer of immunotherapies for oncology and infectious diseases today announced the…
kchenJuly 6, 2021
Although mutations in DNA are the best-studied source of neoantigens that determine response to immune…
kchenJuly 5, 2021
On June 9, Fred Hutchinson Cancer Research Center leaders unveiled two new awards honoring employees…
kchenJuly 5, 2021
